In after-hours trade Tuesday, Supernus Pharmaceuticals (SUPN) shares soared more than 24% percent to $27.99, following the firm revealed promising findings from a trial of its new treatment for attention deficit hyperactivity disorder, or ADHD. Supernus reported Tuesday afternoon that its intended goal was met in a phase 3 trial of the medication, known as SPN-812, in adults.
The Food and Drug Administration is actively reviewing the drug for use in children aged 6 to 17, and once it is approved by the FDA, Supernus plans to ask that the drug be considered for adults as well.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Shares surged more than 40% as trades resumed after the end of after-hours trading Tuesday afternoon, but gradually declined to around 20 percentsurge by the end of the extended session.